Sie sind hier

Startseite » Gyeonggi-Do

NEL BIOTECH CO., LTD.

NEL BIOTECH CO., LTD. ist ein Südkorea Unternehmen, befindet sich in 808-15, Duksan-Ri, Sanjuk-Myon Ansug-Si Gyeonggi-Do 456-880. Mehr Einzelheiten sind wie folgt:

Unternehmensinformation

  • Name des Unternehmens: NEL BIOTECH CO., LTD.
  • Land: South Korea
  • Adresse: 808-15, Duksan-Ri, Sanjuk-Myon Ansug-Si Gyeonggi-Do 456-880
  • Internationale Vorwahl: 82
  • Telefonieren: 82-31-6740531
  • Fax: 82-31-6740534
  • Kontakt: Kyu-hwan Oh
  • Webseite:
  • Artikelliste: Chemicals, Plastics, and Raw Materials Fertilizers, Pesticides, and Agrochemicals
  • Arbeitnehmer: 11 - 50
  • Typ: Manufacturer
  • Gründungsjahr: 1997
  • Profil: The high-functioning feed additives manufactured at NEL Biotech and supplied to various leading feed companies of Korea and overseas, has secured its position as one of the best environment friendly, immunity boosters. And high-functioning fertilizer used for organic faming is an essential element for producing high quality brand farm produces. And following the construction of veterinary medicine factory in September, 2000, we acquired KVGMP(Korean Veterinary Good Manufacturing Practice) in June, 2002, received permit for production of veterinary medicine and feed additives in May, 2003, thus it is more likely to produce more differentiated and excellent quality veterinary medicine. We are certain that environment products, which we have concentrated on developing new products based on our advanced technology, will contribute greatly in improving livestock farming condition due to its excellent effect. Also food business that has been promoted together with the government and academy cooperation is expected to enter an epochal period this year. NEL Biotech will keep on reinforcing top-notch specialists and researchers.
  • Bereich: Gyeonggi-Do
Weitere Links

  • NEKO CORPORATION
  • NEKO TRADING COMPANY
  • NEL BIOTECH CO., LTD.
  • NEL BIOTECH CO., LTD.
  • NELSON KOREA PHARMACEUTICAL COMPANY

    •         ‹ vorherige Seite | nächste Seite ›
    • Zum Verfassen von Kommentaren bitte Anmelden.